Claims for Patent: 10,414,752

Summary for Patent: 10,414,752

Title:	Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Abstract:	The application relates to an inhibitor of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula (I-13):
Inventor(s):	Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
Assignee:	Forma Therapeutics Inc
Application Number:	US15/964,844
Patent Claims:	1. A composition comprising a compound of Formula (I-13) in an enantiomeric purity (e.e. %) of at least 98% as determined by chiral HPLC analysis: 2. The composition of claim 1, further comprising a compound of Formula (III-1): 3. The composition of claim 1, further comprising a compound of Formula (II-1): 4. The composition of claim 3, further comprising a compound of Formula (III-1): 5. The composition of claim 1, wherein the compound of Formula (I-13) is obtained by a process comprising the step of reacting a compound of Formula (II-1) with a compound of Formula (III-1) to obtain the compound of Formula (I-13): 6. The composition of claim 1, further comprising a compound of Formula (V-2): 7. The composition of claim 1, further comprising a compound of Formula (IV-1) 8. The composition of claim 1, wherein the compound of Formula (I-13) is obtained by a process comprising the step of reacting a compound of Formula (IV-1) with a compound of Formula (V-2): 9. A pharmaceutical composition for inhibiting mutant IDH1, comprising a mutant IDH1 inhibitor consisting of a compound of Formula (I-13) in an enantiomeric purity (e.e. %) of at least 98% as determined by chiral HPLC analysis, and a pharmaceutically acceptable carrier: 10. The pharmaceutical composition of claim 9, formulated in a dosage form for oral administration. 11. The pharmaceutical composition of claim 10, formulated in a solid dosage form for oral administration. 12. The pharmaceutical composition of claim 9, formulated as a tablet or capsule dosage form. 13. The pharmaceutical composition of claim 11, comprising a total of about 50 mg of a compound of Formula (I-13). 14. The pharmaceutical composition of claim 11, comprising a total of about 150 mg of a compound of Formula (I-13). 15. The pharmaceutical composition of claim 9, further comprising a compound of Formula (II-1): 16. The pharmaceutical composition of claim 15, further comprising a compound of Formula (III-1): 17. The pharmaceutical composition of claim 9, further comprising a compound of Formula (III-1): 18. The pharmaceutical composition of claim 9, wherein the compound of Formula (I-13) is obtained by a process comprising the step of reacting a compound of Formula (II-1) with a compound of Formula (III-1) to obtain the compound of Formula (I-13): 19. A pharmaceutical composition for inhibiting mutant IDH1, comprising a pharmaceutically acceptable carrier and from about 5% to about 90% by weight of a mutant IDH1 inhibitor consisting of the compound 5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl] amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile. 20. The pharmaceutical composition of claim 19, formulated as a solid dosage form for oral administration, and comprising about 50-150 mg of the compound 5-{[(1S)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl] amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile in an enantiomeric purity (e.e. %) of at least 98% as determined by chiral HPLC analysis.